24
https://pubmed.ncbi.nlm.nih.gov/38112262
The sentence: “Cedirogant, an inverse agonist of RORγt, showed dose-proportional pharmacokinetics, good safety profile, and numerical improvement in psoriasis symptoms in a phase I study, supporting its advancement to phase II clinical trial.”